Xiaomei Liu1, Heng Liu2, Caijun Yuan1, Yinxu Zhang3, Wei Wang1, Shuding Hu3, Lei Liu3, Ying Wang1. 1. Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, P.R. China. 2. Department of Oncology, Liaohe Oil Field General Hospital, Panjin 124000, P.R. China. 3. Department of Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, P.R. China.
Abstract
AIM: This study is aimed to determine whether trimethylamine-N-oxide (TMAO) is a predictor of prognosis of patients with colorectal cancer. METHODS: Pretreatment TMAO serum levels were determined in 108 patients with colorectal cancer and 30 healthy controls. RESULTS: Median serum TMAO level was significantly higher in colorectal cancer patients than in healthy controls (p < 0.01). No correlation was observed between the disease-free survival and the type of chemotherapy regimen used, tumor location or lymphovascular invasion. Patients with high serum TMAO level had significantly shorter disease-free survival than patients with low serum TMAO level. Multivariate analysis showed that serum TMAO level and distant metastases were independent prognostic factors. CONCLUSION: Pretreatment serum TMAO level is identified as a new independent prognostic biomarker in patients with colorectal cancer.
AIM: This study is aimed to determine whether trimethylamine-N-oxide (TMAO) is a predictor of prognosis of patients with colorectal cancer. METHODS: Pretreatment TMAO serum levels were determined in 108 patients with colorectal cancer and 30 healthy controls. RESULTS: Median serum TMAO level was significantly higher in colorectal cancerpatients than in healthy controls (p < 0.01). No correlation was observed between the disease-free survival and the type of chemotherapy regimen used, tumor location or lymphovascular invasion. Patients with high serum TMAO level had significantly shorter disease-free survival than patients with low serum TMAO level. Multivariate analysis showed that serum TMAO level and distant metastases were independent prognostic factors. CONCLUSION: Pretreatment serum TMAO level is identified as a new independent prognostic biomarker in patients with colorectal cancer.
Authors: Carmen Wing Han Chan; Bernard Man Hin Law; Mary Miu Yee Waye; Judy Yuet Wa Chan; Winnie Kwok Wei So; Ka Ming Chow Journal: J Cancer Date: 2019-10-08 Impact factor: 4.207
Authors: Lidia Sánchez-Alcoholado; Rafael Ordóñez; Ana Otero; Isaac Plaza-Andrade; Aurora Laborda-Illanes; José Antonio Medina; Bruno Ramos-Molina; Jaime Gómez-Millán; María Isabel Queipo-Ortuño Journal: Int J Mol Sci Date: 2020-09-16 Impact factor: 5.923